Review
Oncology
W. Glenn McCluggage, Tjalling Bosse, C. Blake Gilks, Brooke E. Howitt, Jessica N. McAlpine, Marisa R. Nucci, Joseph T. Rabban, Naveena Singh, Karen L. Talia, Carlos Parra-Herran
Summary: An updated FIGO staging system for endometrial carcinoma was introduced in June 2023, incorporating non-anatomical parameters to make staging more personalized and relevant. The authors propose a global evaluation to understand the impact, scope, and supporting evidence of the proposed changes.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Jonathan S. Berek, Xavier Matias-Guiu, Carien Creutzberg, Christina Fotopoulou, David Gaffney, Sean Kehoe, Kristina Lindemann, David Mutch, Endometrial Canc Staging Subcomm, FIGO Womens Canc Comm
Summary: Since the 2009 update of the FIGO staging system, there have been significant advances in understanding the pathologic and molecular features of endometrial cancer. The new staging system aims to better define prognostic groups and create substages to guide more appropriate treatment.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2023)
Article
Obstetrics & Gynecology
Jonathan Berek, Xavier Matias-Guiu, Carien Creutzberg, Christina Fotopoulou, David Gaffney, Sean Kehoe, Kristina Lindemann, David Mutch, Nicole Concin, Endometrial Canc Staging Subcomm, FIGO Womens Canc Comm
Summary: Since the last update of the FIGO staging system in 2009, significant advancements have been made in understanding the pathology and molecular features of endometrial cancer. The new staging system aims to better define prognostic groups and create substages that guide appropriate treatment options. The proposed system incorporates data from molecular and histological classifications, providing a more comprehensive understanding of the complex nature of endometrial carcinoma and its biological behavior.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2023)
Article
Medicine, General & Internal
Dario de Biase, Thais Maloberti, Angelo Gianluca Corradini, Francesca Rosini, Marco Grillini, Martina Ruscelli, Sara Coluccelli, Annalisa Altimari, Elisa Gruppioni, Viviana Sanza, Daniela Turchetti, Andrea Galuppi, Martina Ferioli, Susanna Giunchi, Giulia Dondi, Marco Tesei, Gloria Ravegnini, Francesca Abbati, Daniela Rubino, Claudio Zamagni, Pierandrea De Iaco, Donatella Santini, Claudio Ceccarelli, Anna Myriam Perrone, Giovanni Tallini, Antonio De Leo
Summary: This study compares the new ESGO/ESTRO/ESP risk stratification system with the previous 2016 recommendations for endometrial carcinoma patients. The results show that the new system provides more accurate identification of low-risk and high-risk patients, potentially allowing a more specific selection of patients for post-operative adjuvant therapy.
FRONTIERS IN MEDICINE
(2023)
Article
Biochemical Research Methods
Zhichao Chen, Xiaoyuan Huang, Yufeng Lv, Yuan Fang, Lili Pan, Zuhuan Gan, Zhong Huang, Wenhao Wei
Summary: A miR-based signature was developed to predict prognosis for patients with uterine corpus endometrial carcinoma (UCEC), showing promise as an independent prognostic predictor. Using differentially expressed miRs, a prognosis index was constructed and validated in an independent test cohort, successfully identifying high-risk individuals. Additionally, the miRs in the signature were found to be involved in various cancer-related pathways.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
(2021)
Article
Oncology
Paulina J. Haight, Courtney J. Riedinger, Floor J. Backes, David M. O'Malley, Casey M. Cosgrove
Summary: This study provides a contemporary report on stage IVB endometrial carcinoma (2009 FIGO criteria) and evaluates the application of the 2023 FIGO staging criteria. The findings suggest that tumor burden and distribution are important prognostic factors. The use of the 2023 FIGO staging criteria resulted in a change in stage for 58% of patients, indicating its significance in risk stratification.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Obstetrics & Gynecology
Alexander B. Olawaiye, Joseph Cotler, Mauricio A. Cuello, Neerja Bhatla, Aikou Okamoto, Sarikapan Wilailak, Chittaranjan N. Purandare, Gerhard Lindeque, Jonathan S. Berek, Sean Kehoe
Summary: This study introduces the revision of FIGO staging for carcinoma of the vulva using a new data-derived approach, which simplifies the staging and makes it more intuitive. The revised staging, based on data analysis, is validated and much simpler than previous versions, showing clear separation between stages and substages.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2021)
Article
Oncology
Yu Lin, Binglin Zheng, Junqiang Chen, Qiuyuan Huang, Yuling Ye, Yong Yang, Yuanmei Chen, Bijuan Chen, Mengxing You, Qifeng Wang, Yuanji Xu
Summary: This study aimed to develop a nomogram model for predicting overall survival (OS) in patients with upper thoracic esophageal squamous cell carcinoma (ESCC) and establish a risk stratification system. The study found that gender, clinical T stage, clinical N stage, and primary gross tumor volume were independent prognostic factors for OS. The nomogram model based on these factors demonstrated favorable predictive performance and outperformed the American Joint Committee on Cancer (AJCC) staging system.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Yucong Li, Rui Chen, Mingming Yuan, Dong Wang, Chunling Fu, Rongrong Chen, Cuirong Lei, Qi Zhou
Summary: This study investigates the feasibility of molecular classification using comprehensive next-generation sequencing techniques and its relationship with survival outcomes in patients with endometrial cancer. The results show that comprehensive next-generation sequencing is a reliable method for stratifying the prognosis of endometrial cancer and has the potential to guide the treatment of patients in clinical practice.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Medicine, General & Internal
Milosz Pietrus, Kazimierz Pitynski, Marcin Waligora, Katarzyna Milian-Ciesielska, Monika Bialon, Artur Ludwin, Klaudia Skrzypek
Summary: CD133 expression in different subcellular compartments of endometrial cancer tissue is associated with clinical characteristics of the tumor, and positive nuclear CD133 expression may be related to an unfavorable prognosis.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
A. Mohamud, C. Hogdall, T. Schnack
Summary: This study compared the prognostic performance of the FIGO 2009 and FIGO 2018 staging systems for cervical cancer in terms of risk stratification, survival, and treatment outcome. The results showed that the FIGO 2018 staging system had improved discriminatory ability for stage I and IV, and lymph node assessment was proven imperative for patients with specific clinical characteristics.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Obstetrics & Gynecology
Xiaoyan Tang, Chenyan Guo, Songping Liu, Jingjing Guo, Keqin Hua, Junjun Qiu
Summary: The revised 2018 FIGO staging system was found to better reflect the survival of cervical cancer patients in a study involving 3238 patients. Restaging according to the 2018 FIGO system showed a clear trend of decreased recurrence-free survival and overall survival with increasing stage. Multivariate Cox analysis identified 2018 FIGO stage, parametrial involvement, and histology as independent prognostic factors for both overall survival and recurrence-free survival. Predictive nomograms based on these factors demonstrated good predictive ability for cervical cancer prognosis.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2021)
Article
Obstetrics & Gynecology
Huixian Miao, Lin Zhang, Yi Jiang, Yicong Wan, Lin Yuan, Wenjun Cheng
Summary: This study aimed to investigate the impact of preoperative hysteroscopy on progression-free survival (PFS) and disease-specific survival (DFS) in endometrial cancer (EC), and to explore the factors contributing to poor clinical outcomes between hysteroscopy and dilation and curettage (D&C). The results showed that preoperative hysteroscopy was associated with reduced PFS and DFS, and increased risk of recurrence in advanced stage EC. However, hysteroscopy appeared to be a safe diagnostic method in early stage EC.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2023)
Review
Oncology
Kelechi Njoku, Chloe E. Barr, Emma J. Crosbie
Summary: Endometrial cancer is the most common gynaecological malignancy in high income countries, and its incidence is increasing. Prognostic biomarkers can help identify high-risk patients and guide treatment strategies. Apart from genomic research, various blood-based biomarkers have shown potential for predicting the risk of endometrial cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
S. Ytre-Hauge, O. O. Salvesen, C. Krakstad, J. Trovik, I. S. Haldorsen
Summary: Texture analysis of preoperative CT images can predict prognostic histopathological features and outcomes in endometrial cancer patients. High tumour entropy is associated with deep myometrial invasion and cervical stroma invasion, high MPP value predicts high-risk histological subtype, and high tumour kurtosis may predict reduced recurrence- and progression-free survival.
CLINICAL RADIOLOGY
(2021)
Article
Oncology
Vera van der Zanden, Neeltje J. van Soolingen, Alain R. Viddeleer, Johannes W. Trum, Frederic Amant, Marian J. E. Mourits, Johanneke E. A. Portielje, Astrid Baalbergen, Esteban T. D. Souwer, Barbara C. van Munster
Summary: The study aimed to assess the association between the loss of lumbar skeletal muscle mass and density during neoadjuvant chemotherapy (NACT) and postoperative complications in older patients with ovarian cancer. The results showed that the loss of skeletal muscle density during NACT was associated with worse postoperative outcomes, including any postoperative complications, infectious complications, and unintended discontinuation of adjuvant chemotherapy. The findings highlight the importance of evaluating skeletal muscle density as a perioperative risk factor in older patients with ovarian cancer.
Article
Genetics & Heredity
Mahmoud Salama, M. Lambertini, M. S. Christianson, Y. Jayasinghe, A. Anazodo, M. De Vos, F. Amant, C. Stern, L. Appiah, T. L. Woodard, R. A. Anderson, L. M. Westphal, R. E. Leach, K. A. Rodriguez-Wallberg, P. Patrizio, Teresa K. Woodruff
Summary: This study compared oncofertility practices for breast cancer in limited versus optimum resource settings and found higher scores in optimum resource settings, with commonly used methods including egg freezing and embryo freezing, while some new technologies are still in the early stages of clinical research.
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
(2022)
Article
Oncology
Emiel A. De Jaeghere, Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens, Peter Vuylsteke, Stephanie Henry, Xuan Bich Trinh, Peter A. van Dam, Sandrine Aspeslagh, Alex De Caluwe, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen K. Van de Vijver, Frederic Amant, Katrien Vandecasteele, Hannelore G. Denys
Summary: The PRIMMO study conducted a phase II trial on patients with pretreated persistent/recurrent/metastatic cervical or endometrial cancer. The study found that pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail had modest but durable antitumor activity, with acceptable but not negligible toxicity.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Multidisciplinary Sciences
Ankur Chakravarthy, Ian Reddin, Stephen Henderson, Cindy Dong, Nerissa Kirkwood, Maxmilan Jeyakumar, Daniela Rothschild Rodriguez, Natalia Gonzalez Martinez, Jacqueline McDermott, Xiaoping Su, Nagayasau Egawa, Christina S. Fjeldbo, Vilde Eide Skingen, Heidi Lyng, Mari Kylleso Halle, Camilla Krakstad, Afschin Soleiman, Susanne Sprung, Matt Lechner, Peter J. I. Ellis, Mark Wass, Martin Michaelis, Heidi Fiegl, Helga Salvesen, Gareth J. Thomas, John Doorbar, Kerry Chester, Andrew Feber, Tim R. Fenton
Summary: This study conducted a comprehensive analysis of 643 cervical squamous cell carcinomas (CSCC) from different regions and identified two subtypes with different prognosis. One subtype was associated with HPV16 and the other subtype was associated with HPV18. However, the prognosis difference cannot be solely attributed to HPV types. The C2 subtype showed distinct genomic alterations and immune-related differences, which may explain its shorter survival.
NATURE COMMUNICATIONS
(2022)
Review
Surgery
Maurits Lange, J. Joris Hage, Refaat B. Karim, Frederic Amant
Summary: Various techniques have been introduced for reduction labiaplasty, but there is no single technique that is optimal for every patient. The choice of technique should be based on anatomical, configurational, and technical considerations, as well as the patient's personal preferences. An algorithm has been developed to guide the choice of technique, considering factors such as resection or retention of the labial free rim, required labial width reduction, labial vascular status, prevention of iatrogenic labial thickening, and preservation of labial sensibility. The choice of techniques includes edge trimming, central spindle form de-epithelialization or full-thickness resection, and modifications of the wedge resection or de-epithelialization technique.
ARCHIVES OF PLASTIC SURGERY-APS
(2023)
Article
Environmental Sciences
Ilana Struys, Eline Verscheure, Liesbeth Lenaerts, Frederic Amant, Lode Godderis, Manosij Ghosh
Summary: Due to the genotoxic consequences of antineoplastic agents on non-cancerous tissue, it is crucial to understand their effects. This study aimed to characterize the genotoxic profile of different classes of antineoplastic drugs using a cell line assay. The results showed increased micronucleus formation with all tested drugs, as well as specific abnormalities for each drug class. These findings can aid in interpreting genotoxic aberrations in patients treated with these drugs.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
(2023)
Article
Oncology
Pien Lof, Ellen G. Engelhardt, Mignon D. J. M. van Gent, Constantijne H. Mom, Fleur M. F. Rosier-van Dunne, W. Marchien van Baal, Harold R. Verhoeve, Brenda B. J. Hermsen, Marjolijn B. Verbruggen, Majoie Hemelaar, Jojanneke M. G. van de Swaluw, Haye C. Knipscheer, Judith A. F. Huirne, Steven M. Westenberg, Willemien J. van Driel, Eveline M. A. Bleiker, Frederic Amant, Christianne A. R. Lok
Summary: This study evaluated cancer-specific distress and treatment satisfaction in patients with an ovarian mass. It found that many patients experienced high cancer-specific distress during the work-up process. However, patients were generally satisfied with their treatment regardless of the diagnosis and treatment location. This suggests that patients' preferences should be considered when developing risk assessment strategies.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Editorial Material
Oncology
Frederic Amant, Joosje H. Heimovaara, Christianne A. R. Lok, Kristel Van Calsteren
Review
Oncology
Fabian De Smedt, Frederique Dessy, Luciano Carestia, Pamela Baldin, Frank Aboubakar Nana, Philippe Clapuyt, Veronique Boon, Frederic Amant, Mina Mhallem Gziri
Summary: Oncogenic rearrangements in the ALK gene are responsible for 5% of NSCLC cases, and ALK inhibitors have significantly improved the outcomes in ALK(+) mNSCLC patients. ALK(+) NSCLC accounts for 38% of cases in women of childbearing age, presenting new challenges in lung cancer and obstetrics research. This study reported a case of a pregnant HIV-infected patient with ALK(+) mNSCLC who had no fetal developmental abnormalities or obstetric complications during treatment with alectinib.
Article
Orthopedics
Maurits Lange, J. Joris Hage, Arend Aalbers, Esther M. K. Wit, Frederic Amant, Marije J. Hoornweg
Summary: Primary intra- or transabdominal transplantation of extended rectus abdominis myocutaneous (ERAM) flap can prevent surgical complications. Delaying the flap can reduce the risk of intra-abdominal flap loss. However, it may lead to other complications.
JOURNAL OF PLASTIC SURGERY AND HAND SURGERY
(2023)
Article
Medicine, General & Internal
Stephanie W. Vrede, Jenneke Kasius, Johan Bulten, Steven Teerenstra, Jutta Huvila, Eva Colas, Antonio Gil-Moreno, Dorry Boll, Maria Caroline Vos, Anne M. van Altena, Jasmin Asberger, Sanne Sweegers, Willem Jan van Weelden, Louis J. M. van Der Putten, Frederic Amant, Nicole C. M. Visser, Marc P. L. M. Snijders, Heidi V. N. Kusters-Vandevelde, Roy Kruitwagen, Xavier Matias-Guiu, Vit Weinberger, Casper Reijnen, Johanna M. A. Pijnenborg
Summary: Patients with low-grade endometrial cancer have a favorable prognosis independent of molecular subgroup. Routine molecular profiling is not supported for patients with low-grade endometrial cancer, highlighting the importance of primary diagnostic tumor grading and selective profiling.
Article
Pharmacology & Pharmacy
David Damoiseaux, Daniel Centanni, Jos H. Beijnen, Frederic Amant, Alwin D. R. Huitema, Thomas P. C. Dorlo
Summary: Information on the distribution of chemotherapeutic drugs to breast milk is limited, and our study aimed to predict chemotherapy distribution in a more realistic breastfeeding population and evaluate the effect of discarding breast milk on potential chemotherapy exposure in infants.
CLINICAL PHARMACOKINETICS
(2023)
Article
Oncology
Jenneke C. Kasius, Rita Trozzi, Johanna Pijnenborg, Thais Baert, Annouschka Laenen, Anne-Sophie Van Rompuy, Ignacio Zapardiel, Giuseppe Vizzielli, Jure Knez, Francesco Fanfani, Frederic Amant
Summary: The study aims to determine the association between molecular classification and disease stage in endometrial cancer, in order to guide surgical approach. 1000 female patients aged 18 or above will be enrolled, and results on staging and oncological outcomes are expected in 2027 and 2029 respectively.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Sander Dumont, Vincent Vandecaveye, Raphaela Carmen Dresen, Els Van Nieuwenhuysen, Thais Baert, Frederic Amant, Valerie Broeckhoven, Toon Van Gorp
Summary: This study aimed to evaluate the diagnostic value of whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) in predicting resectable disease during secondary cytoreductive surgery for relapsed epithelial ovarian cancer. The study found that WB-DWI/MRI accurately predicted resectable disease and was associated with improved progression-free and overall survival of the patients.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Obstetrics & Gynecology
Teska Schuurman, Ji-Ying Song, Vera Wolters, Marieke van de Ven, Nienke van Trommel, Ina Beerendonk, Frederic Amant, Christianne Lok
Summary: This study found that chemotherapy can cause damage to the maternal ovaries during pregnancy, and the extent of this damage depends on the type of chemotherapy and the duration of exposure. Short-term exposure leads to more severe damage, but it might be temporary. Chemotherapy also results in the loss of primordial follicles and DNA damage, with paclitaxel causing the least damage.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2023)
